Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss

• Sponsor: University of British Columbia (Other)
• Overall Status: Completed
• CT.gov ID: NCT00175617
• Collaborator: (none)
• Enrollment: 40
• Location: 1
• Duration (Months): 42.2
• Patients Per Site Per Month: 0.9

Study Details

Study Description

Brief Summary

This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.

Condition or Disease	Intervention/Treatment	Phase
Female Pattern Hair Loss	Drug: Spironolactone; Drug: Minoxidil	Phase 2

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 40 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Efficacy of Therapy With the Anti-androgen Spironolactone Compared to Topical Minoxidil in Female Pattern Hair Loss
• Study Start Date: Sep 1, 2005
• Actual Primary Completion Date: Mar 9, 2009
• Actual Study Completion Date: Mar 9, 2009

Outcome Measures

Primary Outcome Measures

1. hair density [after 3, 6 and 9 months]

Secondary Outcome Measures

1. percentage of subjects who experience side effects []

2. subject assessment of treatment effect []

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Subjects must be premenopausal women older than 18 with female pattern hair loss.

Exclusion Criteria:

• Androgen excess

• Other scalp or hair disorders

• Contraindications to spironolactone treatment, especially pregnancy, electrolyte imbalances, history of breast cancer, or intake of interfering drugs

• Contraindications to minoxidil treatment, especially patients who are allergic to this treatment or have a history of low blood pressure or irregular heart beats

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	UBC Division of Dermatology, Hair Research and Treatment Centre	Vancouver	British Columbia	Canada	V6G 1Y6

Sponsors and Collaborators

• University of British Columbia

Investigators

• Principal Investigator: Jerry Shapiro, MD, University of British Columbia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: University of British Columbia
• ClinicalTrials.gov Identifier: NCT00175617
• Other Study ID Numbers: C05-0060
• First Posted: Sep 15, 2005
• Last Update Posted: Mar 3, 2017
• Last Verified: Mar 1, 2017

• Additional relevant MeSH terms: Alopecia; Alopecia Areata; Minoxidil; Spironolactone

Study Results

No Results Posted as of Mar 3, 2017